title: [Effect of cyclosporine and simulect mono and combination therapy on cardiac allo-transplantation in rats].
abstract: OBJECTIVE
  To observe the effect of cyclosporine and simulect mono or combination therapy on cardiac allo-transplantation in rats.
  
  
  METHODS
  Recipients with allografts were treated with different doses of cyclosporine and/or simulect after cardiac allo-transplantation. Graft survival time was observed; the histopathological examination of graft tissues was performed; and levels of serum IL-2 and IL-4 were determined.
  
  
  RESULTS
  Mono or combination therapy with cyclosporine and/or simulect increased the survival of cardiac allografts. With the prolongation of survival time of the grafts, the rejection of grafts was moderated. The serum IL-2 level increased in acute rejected grafts; the serum IL-4 level increased evidently in long survival grafts.
  
  
  CONCLUSIONS
  Cyclosporine and simulect have an effect in the prolongation of cardiac allograft survival in rats, and the combination therapy shows an evident synergistic effect.
authors.affiliation: Institute of Transplantation, Third Xiangya Hospital, Central South University, Changsha, China. haiboxiong@hotmail.com
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Xiong
authors.forename: Sui-Sheng
authors.initials: SS
authors.lastname: Xia
authors.forename: Zu-Fal
authors.initials: ZF
authors.lastname: Huang
authors.forename: Qi-Fa
authors.initials: QF
authors.lastname: Ye
authors.forename: Hao
authors.initials: H
authors.lastname: Wen
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D000077552:Basiliximab; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D016027:Heart Transplantation / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D011993:Recombinant Fusion Proteins / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab